# Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV)

> **NCT04120506** · PHASE4 · COMPLETED · sponsor: **Shaare Zedek Medical Center** · enrollment: 15 (actual)

## Conditions studied

- Gaucher Disease, Type 1

## Interventions

- **DRUG:** VPRIV

## Key facts

- **NCT ID:** NCT04120506
- **Lead sponsor:** Shaare Zedek Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-10
- **Primary completion:** 2017-01-20
- **Final completion:** 2022-01-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2022-10-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04120506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04120506, "Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04120506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*